Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.

Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose JM, Weinstein S, Li EC, Demartino J; NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group..

J Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S7-S27.

PMID:
20947724
2.

Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.

Shane R.

Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S6-S12. doi: 10.2146/ajhp090461.

PMID:
19966079
3.

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM.

J Natl Compr Canc Netw. 2011 Sep;9 Suppl 4:S1-22.

PMID:
21976013
4.

The process of NCCN guidelines adaptation to the Middle East and North Africa region.

Jazieh AR, Azim HA, McClure J, Jahanzeb M.

J Natl Compr Canc Netw. 2010 Jul;8 Suppl 3:S5-7.

PMID:
20697132
5.

Understanding risk evaluation and mitigation strategies in organ transplantation.

Gabardi S.

Pharmacotherapy. 2011 Jul;31(7):714-22. doi: 10.1592/phco.31.7.714. Review.

PMID:
21923459
6.

APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.

American Pharmacists Association, Bough M.

J Am Pharm Assoc (2003). 2011 May-Jun;51(3):340-58. doi: 10.1331/JAPhA.2011.11519.

PMID:
21555285
7.

Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.

Kirschenbaum BE.

Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S13-20. doi: 10.2146/ajhp090462.

PMID:
19966075
8.

The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.

Meyer BM.

Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S3-5. doi: 10.2146/ajhp090460.

PMID:
19966078
9.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

10.
11.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology..

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
12.

Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.

Childs L, Alexander E, Duong MT.

Am J Health Syst Pharm. 2012 May 15;69(10):885-9. doi: 10.2146/ajhp110356.

PMID:
22555085
13.

American Society of Clinical Oncology guidance statement: the cost of cancer care.

Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, Ubel PA, Schnipper LE; American Society of Clinical Oncology..

J Clin Oncol. 2009 Aug 10;27(23):3868-74. doi: 10.1200/JCO.2009.23.1183. Epub 2009 Jul 6.

PMID:
19581533
14.

NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2011 Dec;9 Suppl 6:S1-16.

PMID:
22203777
16.

Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop.

Frame JN, Jacobson JO, Vogel WH, Griffith N, Wariabharaj D, Garg R, Zon R, Stephens CL, Bialecki AM, Bruinooge SS, Allen SL.

J Oncol Pract. 2013 Mar;9(2):e24-39. doi: 10.1200/JOP.2012.000620.

17.

Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.

Wright C 4th, Schnoll S, Bernstein D.

Ann N Y Acad Sci. 2008 Oct;1141:284-303. doi: 10.1196/annals.1441.026. Review.

PMID:
18991964
18.

Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.

Nicholson S, Peterson J, Yektashenas B.

Expert Opin Drug Saf. 2012 Mar;11(2):299-314. doi: 10.1517/14740338.2012.650689. Epub 2012 Jan 10. Review.

PMID:
22233294
19.

Stakeholders urge overhaul of REMS programs: Standardization, better access, less paperwork sought.

Traynor K.

Am J Health Syst Pharm. 2010 Sep 1;67(17):1397-8. doi: 10.2146/news100059. No abstract available. Erratum in: Am J Health Syst Pharm. 2010 Sep 15;67(18):1499.

PMID:
20720233

Supplemental Content

Support Center